Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Note: the #DCVax-L phase 3 had MORE MGMT- than the expected #gbm #glioblastoma population (48% v 42%) and FEWER MGMT+ (39.6% v 58%). Even with that crappy roll of the dice, $nwbo still easily beat external matched controls.
— rj (@sharpie510) September 15, 2024
💪https://t.co/ApO8HBda7yhttps://t.co/NKQQ7SAAg2 pic.twitter.com/fRtDTmtDKa
"Batch" followed with "certification" sounded good.
MHRA UPDATE!
— rj (@sharpie510) September 11, 2024
10/09/2024 (September 10, 2024)
UK MIA 54923
ADVENT BIOSERVICES LTD
MANUFACTURING OPERATIONS (according to part 1)$nwbo #dcvax #glioblastoma #gbmhttps://t.co/0iwAgtrQE2
The #glioblastoma survival rate equaled 15.7% at 48 months, 13% at 60 months, a more than twofold reduction in the risk of death. Among 64 patients with recurrent cancer, a 42% reduction in risk of death was indicated (13.2 vs 7.8 months).
— rj (@sharpie510) July 11, 2024
💪$nwbo #dcvaxhttps://t.co/sTViFBvXYL pic.twitter.com/eI22203UaF
Dr. Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, has been elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.$nwbo #dcvax #glioblastomahttps://t.co/XmmJB5yJ4S
— rj (@sharpie510) July 10, 2024
"This is a trial that had some success and is actually at the moment going for registration and it's an immunotherapy trial with a treatment called dendritic cell vaccination."
— rj (@sharpie510) July 9, 2024
🤞
The DCVax® Platform For All Solid Tumor Cancers
💪$nwbo #glioblastoma #gbmhttps://t.co/ImH9pyx6ui
$nwbo #dcvax #glioblastoma #gbm #NonToxic #CancerVaccine #CancerMoonshot $mrk $bmy $rhhby $azn $pfe
— rj (@sharpie510) June 28, 2024
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪 https://t.co/8sSVRykLkh
No, the "Possibly" was in reply to meirluc's timeline for the decision. What I quoted in my post was the actual text the person at MHRA stated to me. The quote is not my speculation, it is what MHRA wrote back to me.
Edit: no wonder I have you on ignore. I wish I could ignore replies as well but here you are.
Possibly, the reply from MHRA also said:
MHRA today told me start date for the #DCVax-L 150-day assessment started on January 24, 2024. 150 days = June 22, 2024. Obviously, this is only a target, not a mandate.
— rj (@sharpie510) June 27, 2024
Any day now.
🤞
LET'S GO $NWBO!
💪
The DCVax® Platform For All Solid Tumor Cancers#Glioblastoma #GBM #Hope pic.twitter.com/skMF65KHhG
#CancerMoonshot $NWBOhttps://t.co/yPQtVWMTH2
— Andrew Caravello, DO (@andrewcaravello) June 19, 2024
#DCVax-L works especially well on the mesenchymal subtype (this subtype performs the WORST on SOC). Recurrent #Glioblastoma tumors tend to shift to mesenchymal which may explain why so many with recurrent #GBM are doing so well on the vaccine!
— rj (@sharpie510) June 13, 2024
👏$nwbo
💪https://t.co/dJfFi7r60U pic.twitter.com/yaduGnYmwL
The wording from MHRA is contradictory. I thought the English prided themselves with being succinct with the language. 😏
At the very top of that link, it says:
Yes: ComputerShare
No: Fidelity, MerrillEdge, Ally
Update – May 2024
— rj (@sharpie510) May 19, 2024
“Stable appearance”.
Joel’s April brain scan continues to show stable post treatment appearance. It is such a relief and extraordinary news.
🫶
The DCVax® Platform For All Solid Tumor Cancers
💪$nwbo #glioblastoma #CancerVaccine
https://t.co/GQxd4PuHRU
$NWBO Going for 2 indications n/r. The MHRA want it. We all want it. They’re going to approve. Don’t over hype; we’re right there. It’s happening. My realistic non emotional timeline. The clock off was for NWBO to educate MHRA, not vice versa. May be sooner. Conservative pic.twitter.com/KHrJXiiAJT
— Gregory Zivic, MD (@metacollectiveG) May 14, 2024
$nwbo #dcvax #glioblastoma https://t.co/irjsMCAx1Y
— rj (@sharpie510) April 29, 2024
Hey Luke,I’m so happy for you that your fortunate enough to get the DCVax-L. I was administered it by my renowned Neurosurgeon Dr. Linda Liau who helped create it, in 2015. 9 years Later I’m still here, no tumor recurrence. It seems we dig the same things photo, movies. Take Care
— Thomas Owen McCaffrey (@ThomasOwenMcCa1) April 29, 2024
The return of the king is significant, said George Gross, the founder of the British Coronations Project at King's College London.
— rj (@sharpie510) April 27, 2024
Dr. Ashkan at King's College London is the EU Lead for the #DCVax-L p3 trial.$nwbo #glioblastomahttps://t.co/5nsP48zNjrhttps://t.co/R57fxNvJkO
Meanwhile, Alice got #DCVax-L for metastatic merkel cell carcinoma (2x deadlier than melanoma). Already 6.5 years after receiving her 1st dose of DCVax-L, she tells her story at ASCO 2018. I believe she's still cancer free today. $nwbo
— rj (@sharpie510) April 26, 2024
Go to 36m:25s mark:https://t.co/Cj9xABpucF
To kick off the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, noted 6 major trends in the 2023 specialty therapy pipeline:https://t.co/McgUeOpUJk$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirector pic.twitter.com/mpA1U2AuvP
— rj (@sharpie510) April 26, 2024
This is fantastic news! Convenience, cost savings, & reduction in hospital visits for patients.
— rj (@sharpie510) April 26, 2024
👏
The DCVax® Platform For All Solid Tumor Cancers$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirectorhttps://t.co/5uzCqiFqWjhttps://t.co/6JnBRLZ3yF
Instead of archaic SOC, why can't he access #DCVax-L for #glioblastoma? Available in UK now, but can't get #CancerVaccine in USA.$nwbo #CancerResearch #ForAllSolidTumors #CancerMoonshot @potus @flotus @nihdirector @ncidirector $mrk $bmy $rhhby $azn $llyhttps://t.co/dpDaNLttb5
— rj (@sharpie510) April 8, 2024
“Tumor lysate-loaded DCs (DCVax-L) have acquired additional T cell stimulatory capacity, resulting in more late generation T cells to fight the tumor” -Marnix Bosch #asco2023 #dcvax $nwbo pic.twitter.com/x6gn4IaQvq
— Allen Turner (@AllenTurner206) June 3, 2023
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) March 3, 2024
Chemotherapy Alters Immune Cell Landscape in Pancreatic Cancer
MARCH 1, 2023
Discovery May Help Explain Immunotherapy Resistance
This article potentially raises some very interesting questions with regards to the future use of Chemotherapy in combination and… pic.twitter.com/Eko9U7XxK3
The paradigm shift begins...
— rj (@sharpie510) April 7, 2024
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪$nwbo #dcvax #glioblastoma #CancerResearch #CancerVaccine #ForAllSolidTumors #CancerMoonshot @potus @flotus @nihdirector @ncidirector $mrk $bmy $rhhby $azn $lly https://t.co/GEgo3sJVZU
TDA/Schwab's ThinkOrSwim app lets you see level 2 for NWBO. The last time I checked Active Trader Pro ~1 year ago, it did not support level 2 for NWBO.
Schwab now charges $6.95 for OTC trades. They probably adopted this from TD Ameritrade when they merged. Fidelity does not charge any commission to buy or sell NWBO or any other OTC stock.
Chemo was billed at $570,000.00 for 10 months before she died. If DCVax can reduce or eliminate chemo, then this paradigm shift, this new standard of care treatment with DCVax, would be much much cheaper and more effective than the current archaic standard of care. Maybe that is why there are so many fudsters out and about trying to kill NWBO and the DCVax platform.
My husband's #GBM SOC, incl surgery = $1M+. But it will recur & there's no SOC for rGBM.
— Lisa🇺🇸🇺🇦 (@LisainNJUSA) March 3, 2024
Along comes #NWBO w/ #DCVAX. With volume, price likely in the 100k ballpark & IT WORKS.
We know BP hates it, but shouldn't HEALTH INSURANCE be stoked for 💰they'll save? Seriously. pic.twitter.com/l0WWgHvVBu
44m:42s, @faulkingtruth on illegal spoofing.
— rj (@sharpie510) March 29, 2024
👏
48m:42s:
"It's not about $mmtlp alone or $amc alone or you know $nwbo alone..."
💪
50m:45s:
"One that's been brought up several times was Northwest Bio and they have a lawsuit..."
🤞#CitadelScandal #APES
💥https://t.co/2rUDzp19wm
Project Orbis specifically will speed up the approval process in each of the participating countries. It just also so happens to be the very countries that NWBO has been going after patents. Hmmmmmmmmmmmmmmmmm
https://g.co/gemini/share/9cab9d5a8b0d
This is why $NWBO has been pursuing patents for #DCVax in IRP & Project Orbis countries:
— rj (@sharpie510) March 10, 2024
FASTER APPROVAL IN ALL OF THEM!
🤞👏💪#glioblastoma #CancerMoonshot @POTUS @FLOTUS $mrk $bmy $rhhby $azn $lly @NIHDirector @NCIDirector https://t.co/Hkt8NkUdsRhttps://t.co/o22ZPqiwpu pic.twitter.com/3wSBQ4wlqq
$NWBO #DCVax-L is awaiting approval, the phase 3 study showed significant improvements in long-term survival. A smaller study combining DCVax-L with immune boosters showed exceptional results. Approval in the UK appears imminent, with approval in the US to follow.💪#glioblastoma https://t.co/ASKA40MYUl
— rj (@sharpie510) March 9, 2024
Today’s FT $NWBO & spoofing! pic.twitter.com/WUphDLODAt
— Richard Fairgrieve (@RichFairgrieve) March 2, 2024
I think this in no way affects the scaling of the EDEN devices. They will always be improving the performance, design and functionality. Perhaps it will make sense in the future to have a single machine processing multiple individual batches, but right now I don't see why they would need to consider that given how small the footprint is for the single batch EDEN they now have. This is a great milestone for Northwest Biotherapeutics and Flaskworks. Being able to fully close, automate, and operate this reliable and inexpensive device (not to mention the process can be repeated in as many devices as needed in lower grade Class C cleanrooms) is something we will all look back on and realize how IMPORTANT this was for the success of the DCVax® franchise. This PR tells everyone they finalized the EDEN device that can be scaled to produce 100s of thousands OR MORE multi-year batches personalized for each patient possible every single year. That would not be possible using the artisan method.
From NIH:
The FDA must make sure that a drug is safe and effective for a specific use. However, it does not control the decision doctors make about which drugs to use for their patients. This means that once the FDA approves a drug, doctors can prescribe it for any purpose they think makes sense for the patient.
Off-label uses may include using an approved drug
for a different type of cancer than the one it is approved to treat
at a different dose or frequency
to treat a child when it is approved to treat adults
Off-label uses of a drug can become approved uses if the company that makes it obtains approval from the FDA. To gain the added approvals, the company must conduct research studies to show that the treatment is safe and effective for the new uses. However, a company may decide not to invest time and money in this research.
https://www.cancer.gov/about-cancer/treatment/drugs/off-label.
Wonderful to hear a #glioblastoma patient can see a path for their life 12 years into the future. Go Tracy!!
— rj (@sharpie510) January 28, 2024
🙏
DCVax-L is the paradigm shift in cancer treatment we've been waiting for.
💪@POTUS @FLOTUS @NCIDirector @NIHDirector $nwbo #dcvax #CancerMoonshot #ForAllSolidTumors https://t.co/ub65uo8cCC pic.twitter.com/l5aWUC2vK4